Beishengyuan (00926) increases investment in ERX and maintains a 3% shareholding, supporting the innovation and development of non-GLP-1 weight loss therapies.

Smart Financial News APP, Beishengyuan (00926) announces that the company expects to record a significant fair value loss of approximately RMB 16.3 million on its investment in ERX Pharmaceuticals Inc. (a clinical-stage biopharmaceutical company registered under Delaware law). The main reason for this fair value loss is the recent change in the US capital market environment, with investors showing a clear preference for technology sectors such as artificial intelligence (AI), leading to a sluggish fundraising activity for traditional drug development and clinical research, causing ERX's new drug development activities to lack external funding. This funding difficulty has put pressure on ERX's short-term valuation, leading to a significant decrease in ERX's valuation.